Evidence map›Paper›PMID 37514962›Full record

ArticleVaccines2023

The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study.

Chuchu Ye, Ge Zhang, Anran Zhang, Hualei Xin, Kang Wu, Zhongjie Li, Yilin Jia, Lipeng Hao, Caoyi Xue, Yuanping Wang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Chuchu YeShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.ORCID 0000-0003-4461-4111
Ge ZhangSchool of Public Health, Dali University, Dali 671003, China.
Anran ZhangShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Hualei XinWorld Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Kang WuShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Zhongjie LiSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100073, China.
Yilin JiaShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Lipeng HaoShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Caoyi XueShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Yuanping WangShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Hongmei XuShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Weiping ZhuShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Yixin ZhouShanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Shanghai Municipal Center For Disease Control Prevention · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNDali University · CNUniversity of Hong Kong · HK

Funding

Pudong New Area Health System Discipline Leader Training Program PWRd2021-15Shanghai Pudong New Area Public Health Peak Discipline "Infectious Disease" Project PWYggf2021-01
6 · The paper itself

Abstract

Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants due to immune escape is challenging for the global response to the pandemic. We estimated the Omicron reinfection prevalence among people who had a previous SARS-CoV-2 infection in Shanghai, China. We conducted a telephone survey in December 2022 with those who had previously been infected with Omicron between March and May 2022. Information on their demographics, coronavirus disease 2019 (COVID-19) testing, and vaccination history was collected. The overall and subgroup reinfection rates were estimated and compared. Among the 1981 respondents who were infected between March and May 2022, 260 had positive nucleic acid or rapid antigen tests in December 2022, with an estimated reinfection rate of 13.1% (95% confidence interval [95% CI]: 11.6-14.6). The reinfection rate for those who had a booster vaccination was 11.4% (95% CI: 9.2-13.7), which was significantly lower than that for those with an incomplete vaccination series (15.2%, 95% CI: 12.3-18.1) (adjusted odds ratio [aOR]: 0.579; 95% CI: 0.412-0.813). Reinfection with the Omicron variant was lower among individuals with a previous SARS-CoV-2 infection and those who had a booster vaccination, suggesting that hybrid immunity may offer protection against reinfection with Omicron sublineages.

Indexed as

COVID-19Omicronreinfectionvaccination

Identifiers

PMID37514962
PMCPMC10386598
OpenAlexW4382137548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.